Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 74% of modeled bridge. Strengths: Occupancy Rate, Net-to-Gross Ratio. Risk-adjusted uplift: $6.6M (vs $8.9M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $3.4M | $3.4M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $3.2M | $93K | $3.3M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $518K | $1.5M | $2.1M | $6.5M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $108K | $108K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 36.9% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $844K | $1.7M | $2.5M | $3.4M | $3.4M | $3.4M | $3.4M |
| Denial Rate Reduction | $0 | $836K | $1.7M | $2.5M | $3.3M | $3.3M | $3.3M | $3.3M |
| A/R Days Reduction | $0 | $685K | $1.4M | $2.1M | $2.1M | $2.1M | $2.1M | $2.1M |
| Clean Claim Rate | $0 | $54K | $108K | $108K | $108K | $108K | $108K | $108K |
| Cumulative | $0 | $2.4M | $4.8M | $7.2M | $8.9M | $8.9M | $8.9M | $8.9M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $8.9M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 45% / 6.3x | 49% / 7.4x | 53% / 8.5x | 55% / 9.0x | 57% / 9.5x |
| 9.0x | 39% / 5.3x | 44% / 6.2x | 48% / 7.2x | 50% / 7.7x | 52% / 8.1x |
| 10.0x | 35% / 4.4x | 39% / 5.3x | 44% / 6.1x | 46% / 6.6x | 48% / 7.0x |
| 11.0x | 30% / 3.7x | 35% / 4.5x | 39% / 5.3x | 41% / 5.7x | 43% / 6.1x |
| 12.0x | 26% / 3.1x | 31% / 3.9x | 36% / 4.6x | 38% / 4.9x | 39% / 5.3x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline -13% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 7.3x, adding 1.1 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $58.1M | — | $58.1M | 34.4% |
| Year 1 | $59.9M | +$5.9M | $65.8M | 39.0% |
| Year 2 | $61.7M | +$8.9M | $70.6M | 41.8% |
| Year 3 | $63.5M | +$8.9M | $72.4M | 42.9% |
| Year 4 | $65.4M | +$8.9M | $74.3M | 44.0% |
| Year 5 | $67.4M | +$8.9M | $76.3M | 45.2% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $1.7M | $2.5M | $3.4M | $4.1M |
| Denial Rate Reductio | $1.7M | $2.5M | $3.3M | $4.0M |
| A/R Days Reduction | $1.0M | $1.5M | $2.1M | $2.5M |
| Clean Claim Rate | $54K | $81K | $108K | $130K |
| Total | $4.4M | $6.7M | $8.9M | $10.7M |
Peer Context — Where This Hospital Sits
Key metrics vs 119 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 34.4% | -6.5% | 5.0% | 14.7% | P96 |
| Net-to-Gross | 10.0% | 12.6% | 19.9% | 36.9% | P12 |
| Occupancy | 80.7% | 51.1% | 64.1% | 76.8% | P81 |
| Rev/Bed | $1.5M | $382K | $696K | $1.2M | P87 |
| Exp/Bed | $979K | $394K | $719K | $1.1M | P66 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.